<SEC-DOCUMENT>0001213900-26-005088.txt : 20260116
<SEC-HEADER>0001213900-26-005088.hdr.sgml : 20260116
<ACCEPTANCE-DATETIME>20260116151246
ACCESSION NUMBER:		0001213900-26-005088
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260116
FILED AS OF DATE:		20260116
DATE AS OF CHANGE:		20260116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		26539137

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0273154-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>January 2026</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tiziana Life Sciences LTD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F
&#9746; &nbsp;Form&nbsp;40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 16, 2026, Tiziana Life Sciences LTD
(the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing, the closing of its previously announced Company best efforts registered
direct offering (&ldquo;Offering&rdquo;) of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without
an underwriter or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering,
before deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, participants
will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and including
July 16, 2026 (when the warrants expire) resulting in additional gross proceeds of up to approximately $10.56 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 31%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: January 16, 2026</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Keeren Shah</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea027315401ex99-1_tiziana.htm">Tiziana Life Sciences LTD Press Release, dated January 16, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027315401ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JANUARY 16, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences Announces Closing of
Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOSTON, MA, January 16, 2026</B> &ndash; Tiziana
Life Sciences, Ltd. (Nasdaq: TLSA) (&ldquo;Tiziana&rdquo;), a biotechnology company developing its lead candidate, intranasal foralumab,
a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct
offering (&ldquo;Offering&rdquo;) of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter
or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering, before
deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, participants will receive
one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and including July 16,
2026 (when the warrants expire) resulting in additional gross proceeds of up to approximately $10.56 million.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering was led by Tiziana&rsquo;s Chief Executive Officer, Ivor Elrifi,
who purchased 2,400,000 ordinary shares, bringing his total holding to 2,757,848 ordinary shares. Executive Chairman and Founder of Tiziana,
Mr. Gabriele Cerrone purchased 1,600,000 ordinary shares in the Offering through Panetta Partners Ltd, an entity in which he has a beneficial
interest, bringing his total holdings to 44,974,830 ordinary shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proceeds from this offering enable the company to complete its
Phase 2 na-SPMS and MSA clinical trials, and achieve top line data readouts in both trials.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities described above are being offered and sold pursuant
to a shelf registration statement on Form F-3 (File No. 333-286064), including a base prospectus, filed with the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) on March 24, 2025, and declared effective on March 27, 2025. The Offering is being made only by means
of a prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or
pricing supplement that the Company may file with the SEC. The final prospectus supplement related to the Offering has been filed with
the SEC and is available on the SEC website.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic
candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory
and neurodegenerative human diseases.<SUP>[1],[2]</SUP></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">[1]</TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">[2]</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana is a clinical-stage biopharmaceutical company developing breakthrough
therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s innovative
nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV)
delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development,
has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology for alternative
routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana and its innovative pipeline of therapies,
please visit www.tizianalifesciences.com.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Statements in this press release may be &ldquo;forward-looking statements&rdquo;
within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from
those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather
are based on the Company&rsquo;s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words
such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo; &lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &rsquo;seeks,&rsquo; &lsquo;estimates,&rsquo; and similar expressions are intended to identify
forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana&rsquo;s management and
include statements regarding the closing of the Offering. These statements are not guarantees of future performance and are subject to
known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&rsquo;s control, are difficult to predict, and
could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions
security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view
of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described
more fully in the section entitled &lsquo;Risk Factors&rsquo; in Tiziana&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2024,
and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only
to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V .P# 2(  A$! Q$!_\0
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MZXKZ(KSGX2^'VL='EUBX0B>^.(P>T0Z?F>:]&KBJRO(^@PE/DIJ_4X+XS?\
M)*M9_P!U/_0UK)_9^_Y)DO\ U^S?^RUK?&8$_"K6< GY4_\ 0UK)_9^!'PQ7
M(ZWLV/\ QVLCJ/1M7_Y M_\ ]>\G_H)KP/\ 9J_Y"FO?]<8O_0C7ONK G1KX
M 9/V>3_T$UX'^S4K?VGKYVG AB!..^30!]#D@ DG '>O)?'_ ,<-,\/&73=
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MMK! #U$487/Y4ZXM;>[B\JY@BFCSG9*@8?D:CL7:33+:1V+.T*L2>Y*BO*_
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M0_[32U:V'FM'Y;/NZ8YS@>M%% &9X-MG@\4>,Y&*D2ZDC+CL/*4<TMW9+/\
M%BUFE2-XUT=UVN,G/FBBB@#KT18T"(H51T"C %>,Q^.HO!7BGQ/9SZ9]K:YU
M1[A764+M!51@@J?2BB@#V2"7SK>.7&-ZAL>F1FI#T.*** /(-4UP^/?$%CH$
M>FP6>HV5ZD[7YE+&-(VR1&0H.6 Q@X'->C^*-!B\3^&;_1I9#$MU$5$@'*-U
M5OP(%%% ' Z7\5+JSUVT\)ZMIB3:JKK;R7-O-B)^0-^"N0>^/UKK?B1 US\.
MM=A0@,]J0">G4444 ;^GJ5TJU4]1 @_\=%>/^ ?'\6CVVF^%Y-*\R87+0FY6
M48^>5CG&W/\ %110!Z'\1(6N/ >J1(0&9$P3T^^M<S\3?#C//IVN6,J12R7%
MO:WJ-G$\?FJR'C^)6'!]":** ._UG2X-;T6]TNY)$-W"T+E>H##&1[UY=:_$
MJ[\&W=GX.UC3X[Z_M]MO'=6\VQ)$& I8%<@XQG&:** /2/%,;3^$-8C4@,]E
M,HSTY0UP?P^^(D%^^D>'!I)BE2V6(SB4$91.3C:.N*** .R\8>)CX5TM+]K,
M741?9(GF;2!CJ.#GZ<5YMIO@F^\9?:O$.F7Z:%9WLY>.SM2Q PJJ6;  W$@D
&XHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
